Yuhan has been granted a patent for a double-stranded oligonucleotide designed to specifically inhibit amphiregulin expression. This invention includes various structural forms and nanoparticles, with potential applications in preventing or treating fibrosis and respiratory diseases. GlobalData’s report on Yuhan gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Yuhan, Cancer treatment biomarkers was a key innovation area identified from patents. Yuhan's grant share as of July 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Double-stranded oligonucleotide for inhibiting amphiregulin expression
The granted patent US12037589B2 outlines a series of claims related to novel compounds characterized by specific structural formulas (3) and (4). The primary focus is on compounds that include amphiregulin-specific DNA sense strands and their complementary RNA antisense strands. The claims detail various sequences for the DNA sense strands, specifically those listed in SEQ ID NO: 1-14, with particular emphasis on sequences 10, 11, and 12. Additionally, the compounds may feature chemical modifications to the DNA or RNA strands, including substitutions at the 2' carbon position of the sugar structure, alterations to the sugar's oxygen, and modifications to the bonds between nucleotides.
Further claims elaborate on the nature of the covalent bonds within these compounds, distinguishing between non-degradable and degradable bonds, with specific examples provided for each type. The patent also covers compounds that incorporate conjugates such as hexosamine, N-acetyl galactosamine, glucose, or mannose. Notably, the claims extend to nanoparticles that contain the described compounds, which may consist of a mixture of double-stranded oligonucleotides with unique DNA sense strand sequences. Lastly, the patent includes claims for pharmaceutical compositions that utilize either the compounds or the nanoparticles as active ingredients, indicating potential applications in therapeutic contexts.
To know more about GlobalData’s detailed insights on Yuhan, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
